Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease

Abroad (travel likely)RecruitingPHASE1

Conditions

Parkinson Disease

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia
Contact: Study coordinator (Umesh Tulachan) · umesh.tulachan@svha.org.au
Contact: Study coordinator (Valerie Bramah) · valerie.bramah@svha.org.au · + 61 2 8382 4977
Southern Neurology, Kogarah, New South Wales, Australia
Contact: Study coordinator (Elena Simon) · elena.simon@southern-neurology.com.au · +61 408455183
Westmead Hospital, Westmead, New South Wales, Australia
Contact: Study coordinator (Sarah Bray) · sarah.bray@health.nsw.gov.au · + 61 28890 6793
Contact: Study coordinator (Cassie Chen) · xi.chen2@health.nsw.gov.au · + 61 438 678 797
Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
Contact: Study coordinator (Schible Kurian) · schible.kurian@health.qld.gov.au · +61 436447386
CMAX, Adelaide, South Australia, Australia
CMAX · PET@cmax.com.au · 1800 150 433
Alfred Health, Melbourne, Victoria, Australia
Contact: Study coordinator (Susan Rose) · susan.rose@alfred.org.au · +61 3 9903 9402
Contact: Study coordinator (Beth Sutherland) · b.sutherland@alfred.org.au · + 61 3 9903 9402
Royal Melbourne Hospital, Parkville, Victoria, Australia
Contact: Study coordinator (Reena Chopra) · reena.chopra@mh.org.au · + 61 3 9342 8182
Contact: Study coordinator (Rebecca Ravenhill) · Rebecca.Ravenhill@mh.org.au · + 61 3 9342 8182

Study leads

Chief Medical Officer
Study Director
Gain Therapeutics, Inc.

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)

Parkinson Disease

Abroad (travel likely)RecruitingEARLY_PHASE1

Birmingham, United States

A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418

Parkinson Disease Psychosis · Amyotrophic Lateral Sclerosis (ALS)

Abroad (travel likely)RecruitingPHASE1

Seoul, South Korea

Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease

Parkinson Disease

Abroad (travel likely)RecruitingPHASE2

Davie, United States · Hialeah, United States

Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation

Parkinson Disease

Abroad (travel likely)Recruiting

Ann Arbor, United States